Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer

Inclusion Criteria: * Female patients, age ≦ 65 years old * Histologically or cytologically confirmed primary breast cancer by core biopsy * Disease stage appropriate for neoadjuvant chemotherapy (T2～T3，N0～2，M0) * No previous treatment for breast cancer * No history of other malignancies * No currently uncontrolled diseased (e.g., ongoing cardiac dysrhythmias, unstable diabetes) or active infection * No history of other malignancies * No currently uncontrolled diseased or active infection * Not pregnant or breast feeding, and on appropriate birth control if of child-bearing potential * Adequate cardiovascular function reserve without a myocardial infarction within the past six month * Adequate hematologic function with: 1. Absolute neutrophil count (ANC) ≥ 1500/mm3 2. Platelets ≥ 100,000/ mm3 3. Hemoglobin ≥ 10 g/dL * Adequate hepatic and renal function with: 1. Serum bilirubin ≤ 1.5×UNL 2. Alkaline phosphatase and alanine aminotransferase (ALT) ≤ 2.5 x ULN. 3. Serum creatinine ≤ 1.7 mg/dl * Knowledge of the investigational nature of the study and Ability to give informed consent * Ability and willingness to comply with study procedures Exclusion Criteria: * Known or suspected distant metastases * Concurrent malignancy or history of other malignancy * Uncontrolled diseases or active infection * Hepatic or renal dysfunction as detailed above * Geographical, social, or psychological problems that would compromise study compliance * Known or suspected hypersensitivity to cyclophosphamide, epirubicin and fluorouracil